Jan 12 (Reuters) - Revvity said on Monday it expects its 2025 adjusted profit per share to exceed its forecast of $4.90 to $5, as the medical equipment maker benefits from renewed demand for contract research and diagnostics services.
The company's shares were up nearly 6% in extended trading.
Pharmaceutical companies have ramped up drug development in the U.S. amid evolving trade policies under President Donald Trump.
Revvity said it expects to report fourth-quarter revenue of around $772 million, above Wall Street estimates of $760.3 million, according to data compiled by LSEG.
It also expects annual revenue to grow 4% to $2.86 billion, above estimates of $2.84 billion.
The company will report its fourth-quarter and full year 2025 results on February 2.
(Reporting by Puyaan Singh in Bengaluru; Editing by Leroy Leo)
LATEST POSTS
- 1
True serenity: Investigating Emotional well-being and the Advantages of Contemplation - 2Vote In favor of Your Favored Comupter Game
- 3How stripping diversity, equity and inclusion from health care may make Americans sicker
- 4How did birds survive while dinosaurs went extinct?
- 5Flu season is ramping up, and some experts are "pretty worried"
- A Manual for Pick Great Lawful Discussion Administrations For New businesses In 2024
- The 15 Most Compelling Books in History
- Watch South Korean startup Innospace attempt its 1st-ever orbital launch today
- Share your number one city visit transport that leaves a mark on the world wake up!
- Far-right leader Le Pen to attend Brigitte Bardot's funeral
- In the stomach of a mummified wolf pup, scientists find DNA from a woolly rhinoceros
- Glen Powell will host 'Saturday Night Live' with Olivia Dean as musical guest: What to know ahead of their debut
- Vote In favor of Your Favored Menial helper Administration
- The most effective method to Go Down Abundance through Ages with Disc Rates
